Under terms of the deal, Regeneron will pay Intellia $70 million up front and make an additional investment in the firm of $30 million in the near future. The new agreement expands the companies' collaboration through April 2024. In preclinical studies, the companies demonstrated a CRISPR/Cas9-mediated targeted transgene insertion in the liver of nonhuman primates, which generated normal or higher levels of circulating human factor IX.

Regeneron will have rights to discover and develop CRISPR/Cas9-based therapeutic products for an additional five in vivo liver targets, for a total of up to 15 targets. Regeneron will also receive a royalty-bearing, nonexclusive license to certain Intellia intellectual property to develop and commercialize up to 10 ex vivo CRISPR/Cas9 products in defined cell types.

MilliporeSigma granted foundational CRISPR-Cas9 U.S. patents
MilliporeSigma announced on May 11 that two of its CRISPR-Cas9-assisted genome-editing patents have been allowed in the U.S. The allowances cover cleavage...

Regeneron inks human genetics research collaboration
Regeneron Pharmaceuticals has established a human genetics research collaboration with the Colorado Center for Personalized Medicine at the University...

Caribou, MaxCyte enter CRISPR license agreement
Caribou Biosciences and MaxCyte have announced a clinical and commercial license agreement for the development of Carbiou's CAR-T cell therapy program.

MilliporeSigma awarded U.S. patent for new CRISPR technology
MilliporeSigma announced that the U.S. Patent and Trademark Office has granted the company's patent for CRISPR-chrom technology. This award is the second...